默克公司的Keytruda获得了卵巢癌、卵巢癌的更多适应症

2026-02-11 06:39

The US FDA has approved Merck's oncologic Keytruda (pembrolizumab) to treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1.
Keytruda in these indications is to be given with paclitaxel, and with or without Avastin (bevacizumab).
Approval was based on the progression-free and overall survival results of the KEYNOTE-B96 trial.
The FDA also approved Agilent Technologies' (A) PD-L1 IHC 22C3 pharmDx companion diagnostic to identify patients with these cancers who might benefit from Keytruda therapy.

More on Merck